Shares of Haemonetics Co. (NYSE:HAE) have been given a consensus rating of “Buy” by the nine brokerages that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $102.67.
HAE has been the topic of a number of research reports. Zacks Investment Research raised shares of Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 price target on the stock in a research note on Friday, October 12th. Barrington Research reaffirmed a “buy” rating and issued a $127.00 price target on shares of Haemonetics in a research note on Friday, October 5th. TheStreet lowered shares of Haemonetics from a “b” rating to a “c+” rating in a research note on Monday, August 20th. Morgan Stanley lifted their price target on shares of Haemonetics from $100.00 to $120.00 and gave the company an “overweight” rating in a research note on Wednesday, August 8th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $125.00 price target on shares of Haemonetics in a research note on Tuesday, August 7th.
NYSE HAE traded up $0.11 during trading on Monday, reaching $105.45. 476,400 shares of the stock traded hands, compared to its average volume of 559,799. The stock has a market cap of $5.45 billion, a P/E ratio of 56.43, a P/E/G ratio of 3.42 and a beta of 1.09. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.94 and a current ratio of 2.84. Haemonetics has a fifty-two week low of $46.79 and a fifty-two week high of $117.56.
Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Tuesday, August 7th. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.42 by $0.17. The firm had revenue of $229.35 million during the quarter, compared to analysts’ expectations of $219.52 million. Haemonetics had a net margin of 2.45% and a return on equity of 15.00%. Analysts predict that Haemonetics will post 2.28 earnings per share for the current fiscal year.
In other news, SVP Jacqueline Scanlan sold 4,890 shares of the business’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $112.19, for a total value of $548,609.10. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Pedro P. Granadillo sold 30,824 shares of the business’s stock in a transaction on Monday, September 17th. The stock was sold at an average price of $111.83, for a total transaction of $3,447,047.92. The disclosure for this sale can be found here. In the last ninety days, insiders sold 37,275 shares of company stock worth $4,069,830. Insiders own 1.04% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Chicago Equity Partners LLC lifted its position in shares of Haemonetics by 34.0% in the second quarter. Chicago Equity Partners LLC now owns 86,665 shares of the medical instruments supplier’s stock worth $7,772,000 after purchasing an additional 22,000 shares in the last quarter. Liberty Mutual Group Asset Management Inc. bought a new stake in shares of Haemonetics in the second quarter worth $932,000. ING Groep NV bought a new stake in shares of Haemonetics in the second quarter worth $485,000. MetLife Investment Advisors LLC lifted its position in shares of Haemonetics by 142.0% in the second quarter. MetLife Investment Advisors LLC now owns 57,955 shares of the medical instruments supplier’s stock worth $5,197,000 after purchasing an additional 34,009 shares in the last quarter. Finally, Boston Partners bought a new stake in shares of Haemonetics in the second quarter worth $1,794,000. 96.44% of the stock is currently owned by institutional investors and hedge funds.
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Featured Article: How Investors Use a Balance Sheet
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.